Leukemia

Investigators are assessing CLN-049 among patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome in a phase 1 study.

Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial.

No patients with frontline acute myeloid leukemia experienced cytokine release syndrome following treatment with mipletamig plus venetoclax/azacitidine.

Preliminary findings have shown an “unprecedented” result with blinatumomab in mixed phenotype acute leukemia, according to Ashkan Emadi, MD, PhD.

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

New guidelines highlight asparaginase as a cornerstone of frontline therapy for adolescents and young adults with acute lymphoblastic leukemia.

Older age appeared to correlate with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

An unadjusted indirect comparison analysis of the SEQUOIA and AMPLIFY trials revealed improved PFS with zanubrutinib vs acalabrutinib plus venetoclax.

Investigators are currently assessing QTX-2101 among patients with acute promyelocytic leukemia in a phase 3 trial.

Approval of the larger vial size may offer more dosing flexibility for pediatric and adult patients with T-cell ALL or LBL.

Data from the ENDURE trial may contextualize prior evidence suggesting an interferon-related improvement in treatment-free remission rates in CML.

Data from a phase 1/2 trial support the FDA’s designation for WU-CART-007 in relapsed/refractory T-cell ALL and T-cell lymphoblastic lymphoma.

Early safety and immunogenicity data may warrant further evaluation of iTAC-XS15-CLL01 among patients with chronic lymphocytic leukemia.

Data from the phase 1/2 EVICTION study support the breakthrough therapy designation for ICT01 plus venetoclax/azacitidine in acute myeloid leukemia.

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.